SCHEMBL3565491

SCHEMBL3565491

CCN(CC)C/C=C/c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.76
AURKA O14965 10/20 0.76
ABL1 P00519 9/20 0.76
LCK P06239 9/20 0.76
CSF1R P07333 9/20 0.76
MET P08581 9/20 0.76
FGFR1 P11362 9/20 0.76
FLT1 P17948 9/20 0.76
FLT3 P36888 9/20 0.76
ROCK1 Q13464 9/20 0.76
NTRK2 Q16620 9/20 0.76
MAP4K4 O95819 8/20 0.76
PTK2 Q05397 8/20 0.76
MAP4K2 Q12851 8/20 0.76
TAOK1 Q7L7X3 8/20 0.76
FYN P06241 8/20 0.76
NEK2 P51955 8/20 0.76
NTRK1 P04629 8/20 0.76
PLK4 O00444 7/20 0.76
ROCK2 O75116 7/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565495 1.00 KDR (0.76) KDRAURKAABL1LCKCSF1R
SCHEMBL3533564 0.93 KDR (0.75) KDRAURKAABL1LCKCSF1R
SCHEMBL3533565 0.93 KDR (0.75) KDRAURKAABL1LCKCSF1R
SCHEMBL3531678 0.86 KDR (1.00) KDRAURKAABL1LCKCSF1R
SCHEMBL3531674 0.86 KDR (1.00) KDRAURKAABL1LCKCSF1R
SCHEMBL3531818 0.85 KDR (0.84) KDRAURKAABL1LCKCSF1R
SCHEMBL3530977 0.85 KDR (0.84) KDRAURKAABL1LCKCSF1R
SCHEMBL3584517 0.85 KDR (0.79) KDRAURKAABL1LCKCSF1R
SCHEMBL3584513 0.85 KDR (0.79) KDRAURKAABL1LCKCSF1R
SCHEMBL3531813 0.85 KDR (0.84) KDRAURKAABL1LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885ABL1 1/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885ABL1 1/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885ABL1 1/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885ABL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.